Ureidopenicillin therapy for acute antepartum pyelonephritis

S. M. Cox, F. G. Cunningham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite a frequency of 1% to 2%, few studies have been designed to evaluate treatment of women with antepartum pyelonephritis. We studied the clinical efficacy of two extended-spectrum ureidopenicillins for the treatment of 190 pregnant women with renal infection. Of these, 150 were treated with mezlocillin and 40 were given piperacillin. The clinical cure rate with either drug was 96%, and 78% responded within 48 hours and another 18% within 96 hours. These drugs were equally well tolerated and were safe and effective with no adverse maternal or fetal outcomes observed.

Original languageEnglish (US)
Pages (from-to)1029-1034
Number of pages6
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume44
Issue number6
StatePublished - 1988

Fingerprint

Pyelonephritis
Mezlocillin
Piperacillin
Pharmaceutical Preparations
Pregnant Women
Mothers
Kidney
Therapeutics
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ureidopenicillin therapy for acute antepartum pyelonephritis. / Cox, S. M.; Cunningham, F. G.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 44, No. 6, 1988, p. 1029-1034.

Research output: Contribution to journalArticle

@article{1c3aa57c80de493cbcd921d139a45a55,
title = "Ureidopenicillin therapy for acute antepartum pyelonephritis",
abstract = "Despite a frequency of 1{\%} to 2{\%}, few studies have been designed to evaluate treatment of women with antepartum pyelonephritis. We studied the clinical efficacy of two extended-spectrum ureidopenicillins for the treatment of 190 pregnant women with renal infection. Of these, 150 were treated with mezlocillin and 40 were given piperacillin. The clinical cure rate with either drug was 96{\%}, and 78{\%} responded within 48 hours and another 18{\%} within 96 hours. These drugs were equally well tolerated and were safe and effective with no adverse maternal or fetal outcomes observed.",
author = "Cox, {S. M.} and Cunningham, {F. G.}",
year = "1988",
language = "English (US)",
volume = "44",
pages = "1029--1034",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Ureidopenicillin therapy for acute antepartum pyelonephritis

AU - Cox, S. M.

AU - Cunningham, F. G.

PY - 1988

Y1 - 1988

N2 - Despite a frequency of 1% to 2%, few studies have been designed to evaluate treatment of women with antepartum pyelonephritis. We studied the clinical efficacy of two extended-spectrum ureidopenicillins for the treatment of 190 pregnant women with renal infection. Of these, 150 were treated with mezlocillin and 40 were given piperacillin. The clinical cure rate with either drug was 96%, and 78% responded within 48 hours and another 18% within 96 hours. These drugs were equally well tolerated and were safe and effective with no adverse maternal or fetal outcomes observed.

AB - Despite a frequency of 1% to 2%, few studies have been designed to evaluate treatment of women with antepartum pyelonephritis. We studied the clinical efficacy of two extended-spectrum ureidopenicillins for the treatment of 190 pregnant women with renal infection. Of these, 150 were treated with mezlocillin and 40 were given piperacillin. The clinical cure rate with either drug was 96%, and 78% responded within 48 hours and another 18% within 96 hours. These drugs were equally well tolerated and were safe and effective with no adverse maternal or fetal outcomes observed.

UR - http://www.scopus.com/inward/record.url?scp=0024241757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024241757&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1029

EP - 1034

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 6

ER -